|MolMed S p A -- Germany Stock|| |
EUR 0.46 0.025 5.15%
Director Clinical Development
Dr. Antonio Lambiase serves as Director of Clinical Development at Molecular Medicine S.p.A. since March 2007. He previously worked for over 15 years at Roche in the areas of oncology and hematology as Medical Responsible for Clinical Development of several biological and molecular targeted compounds, including cancer bio therapeutics, hematopoietic growth factors, and therapeutic monoclonal antibodies and antiangiogenesis agents. Before that, he spent three years as Research Fellow at the Medical Oncology Unit of National Cancer Institute of Milan. He gained a degree in Medicine from Universita degli Studi di Napoli Federico II and a Doctorate of Medicine in Medicine from Universita degli Studi di Napoli Federico II.
Age: 55 Director Since 2007 Ph.D
39 02 21 27 71 http://www.molmed.com
The company has return on total asset (ROA)
of (18.1) %
which means that it has lost $18.1 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (61.21) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 964 K in total debt with debt to equity ratio (D/E) of 6.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. MolMed S p A has Current Ratio of 1.37 which is within standard range for the sector.
MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of anticancer therapies. MolMed S.p.A. was founded in 1996 and is headquartered in Milan, Italy. MolMed S is traded on Frankfurt Stock Exchange in Germany.MolMed S p A (4HW) is traded on Frankfurt Stock Exchange in Germany. It is located in Via Olgettina, 58 and employs 23 people.